Ranibizumab (RG-6321) 是一种人源化的抗?VEGF?单克隆抗体片段，能够识别所有 VEGF-A 亚型 (VEGF110，VEGF121，以及 VEGF165)。动物模型中，Ranibizumab 减缓视力丧失，并用于老年黄斑变性 (AMD) 的研究。
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1].
(In Vitro)
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317). Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures.
(In Vivo)
Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6–24?h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1?h after intravitreal administration in rabbits.
In a study comparing the pharmacokinetics of 0.5?mg of intravitreal Ranibizumab with 1.25?mg of intravitreal Bevacizumab in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7?μg/ml for Bevacizumab and 17.9?μg/ml for Ranibizumab, respectively.
动态评分
0.0